Please assess the completion status of the following clinical trial:

Trial Title: Trial of Yellow Fever Inactivated Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All aspects of the protocol explained and written informed consent obtained from the subject;~* Aged 18 to 49 years, inclusive;~* In good general health, without significant medical history, physical examination findings, or abnormal laboratory results; and~* Subject must be available for the study duration, including all planned follow-up visits.~* For female subjects of child bearing potential: Negative serum pregnancy tests at Day -7 to -1, and negative urine pregnancy tests prior to vaccination on Days 0, in conjunction with a menstrual and contraceptive history indicating a low probability of pregnancy in the opinion of the physician. Females of childbearing potential will be required to be correctly using an efficacious hormonal method of contraception or intrauterine device for at least 1 month before randomization and during the on-study phase to Day 42. Barrier methods of contraception will not be considered acceptable for study entry. Female subjects of child-bearing potential will acknowledge by signing their informed consent that contraception will be correctly practised during the specified periods and will specify the method used. Female subjects unable to become pregnant must have this documented (e.g. tubal ligation, hysterectomy or postmenopausal \[at least one year since last menstrual period\]).~Exclusion Criteria:~* History of travel to South America or SubSaharan Africa;~* History of active duty military service;~* History of vaccination against yellow fever, tick-borne encephalitis (TBE), or Japanese encephalitis;~* Went to primary (grade) school in Austria, Germany, Japan, South Korea, India, Thailand, Nepal, Vietnam, or Taiwan (where TBE vaccination is practiced)~* History of dengue fever;~* Known or suspected immunodeficiency disorder, including leukemia, lymphoma, generalized malignancy, or treatment with immunosuppressive medications, including corticosteroids, alkylating agents, antimetabolites, or radiation therapy. Low dose steroids (≤ 10 mg prednisone or equivalent, topical or intra-articular/bursal/tendon/epidural injections of corticosteroids) do not constitute a reason for exclusion;~* History of an autoimmune disorder, including systemic lupus, rheumatoid arthritis, scleroderma, other collagen vascular disease, multiple sclerosis, etc. Psoriasis limited to cutaneous manifestations is not an exclusion criterion;~* Prior history of anaphylaxis to foods, hymenoptera stings, vaccines or drugs;~* Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within 3 months of the Screening Visit or anticipated up to Study Day 42;~* Administration of another vaccine within 30 days preceding the screening visit or anticipated up to Day 42 (these subjects may be rescheduled for vaccination at a later date);~* Participation in another clinical trial within 60 days of the screening visit;~* Positive serum or urine pregnancy test prior to vaccination (women of child-bearing potential or lactation or intended pregnancy during study period);~* Abnormalities on laboratory assessment (i.e. meeting the criteria defined for a mild, moderate or severe adverse event in Appendix 1, a1A);~* Seropositive to HIV or HCV or positive for HBsAg;~* Physical examination indicating any clinically significant medical condition;~* Body temperature \>38.1°C (100.6°F) or acute illness within 3 days prior to vaccination (subject may be rescheduled);~* Intention to travel out of the area prior to the study visit on Day 42;~* History of excessive alcohol consumption, drug abuse, significant psychiatric illness; and~* Intention to increase normal exercise routine, participate in contact sports or strenuous weight lifting or to initiate vigorous exercise from Screening until after Day 42.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- High dose (Type: ACTIVE_COMPARATOR): None
- Mid Dose (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): NaCl Injectable 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).